Resistance to PARP-inhibitors in Cancer Therapy

Resistance to PARP-inhibitors in Cancer Therapy

The pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) family of proteins have shown promising results in preclinical studies and clinical trials as a monotherapy or in combination therapy for some cancers. Thus, usage of PARP-inhibitors (PARPi) in cancer therapy is bound to increase w...

Full description

Bibliographic Details
Main Authors: Alicia eMontoni, Mihaela eRobu, Emilie ePouliot, Girish M. Shah
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-02-01
Series:Frontiers in Pharmacology
Subjects:
DNA Damage
DNA Repair
Homologous Recombination
synthetic lethality
Poly(ADP-ribose) polymerase (PARP)
Inhibitors of PARP
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00018/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00018/full

Similar Items